173 related articles for article (PubMed ID: 30527643)
1. The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.
Kucharczyk MJ; Gravis G; Niazi T
Eur Urol Focus; 2019 Mar; 5(2):117-118. PubMed ID: 30527643
[TBL] [Abstract][Full Text] [Related]
2. The biology of prostate cancer metastases: does oligo differ from polymetastatic?
Sonpavde G
Curr Opin Urol; 2017 Nov; 27(6):542-546. PubMed ID: 28786848
[TBL] [Abstract][Full Text] [Related]
3. Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
James ND
Eur Urol Focus; 2019 Mar; 5(2):119-122. PubMed ID: 30803925
[TBL] [Abstract][Full Text] [Related]
4. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract][Full Text] [Related]
5. What Is Oligometastatic Prostate Cancer?
Fraser M; Koontz B; Emmenegger U; De Meerleer G; Khoo V; Feng F; Corcoran NM; Hovens CM; Tran PT; Ost P; Boutros PC;
Eur Urol Focus; 2019 Mar; 5(2):159-161. PubMed ID: 30642810
[TBL] [Abstract][Full Text] [Related]
6. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.
Joice GA; Rowe SP; Pienta KJ; Gorin MA
Curr Opin Urol; 2017 Nov; 27(6):533-541. PubMed ID: 28863016
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targets.
Fenderico N; Casamichele A; Profumo V; Zaffaroni N; Gandellini P
Curr Med Chem; 2013; 20(12):1566-84. PubMed ID: 23410173
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as Regulators of Prostate Cancer Metastasis.
Bhagirath D; Yang TL; Dahiya R; Saini S
Adv Exp Med Biol; 2018; 1095():83-100. PubMed ID: 30229550
[TBL] [Abstract][Full Text] [Related]
9. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
Lecouvet FE; Oprea-Lager DE; Liu Y; Ost P; Bidaut L; Collette L; Deroose CM; Goffin K; Herrmann K; Hoekstra OS; Kramer G; Lievens Y; Lopci E; Pasquier D; Petersen LJ; Talbot JN; Zacho H; Tombal B; deSouza NM
Lancet Oncol; 2018 Oct; 19(10):e534-e545. PubMed ID: 30303127
[TBL] [Abstract][Full Text] [Related]
10. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).
D'Angelillo RM; Francolini G; Ingrosso G; Ravo V; Triggiani L; Magli A; Mazzeo E; Arcangeli S; Alongi F; Jereczek-Fossa BA; Pergolizzi S; Pappagallo GL; Magrini SM
Crit Rev Oncol Hematol; 2019 Jun; 138():24-28. PubMed ID: 31092381
[TBL] [Abstract][Full Text] [Related]
11. Oligometastasis: Past, Present, Future.
Gutiontov SI; Pitroda SP; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):530-538. PubMed ID: 32976785
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs and prostate cancer: from preclinical research to translational oncology.
Maugeri-Saccà M; Coppola V; Bonci D; De Maria R
Cancer J; 2012; 18(3):253-61. PubMed ID: 22647362
[TBL] [Abstract][Full Text] [Related]
13. The biology and clinical implications of prostate cancer dormancy and metastasis.
Morrissey C; Vessella RL; Lange PH; Lam HM
J Mol Med (Berl); 2016 Mar; 94(3):259-65. PubMed ID: 26489605
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology of prostate cancer.
Karayi MK; Markham AF
Prostate Cancer Prostatic Dis; 2004; 7(1):6-20. PubMed ID: 14999233
[TBL] [Abstract][Full Text] [Related]
15. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
Kim J; Park JS; Ham WS
Investig Clin Urol; 2017 Sep; 58(5):307-316. PubMed ID: 28868501
[TBL] [Abstract][Full Text] [Related]
16. The index lesion and the origin of prostate cancer.
Ahmed HU
N Engl J Med; 2009 Oct; 361(17):1704-6. PubMed ID: 19846858
[No Abstract] [Full Text] [Related]
17. Oligometastatic prostate cancer: Reality or figment of imagination?
Foster CC; Weichselbaum RR; Pitroda SP
Cancer; 2019 Feb; 125(3):340-352. PubMed ID: 30521067
[TBL] [Abstract][Full Text] [Related]
18. [Oligometastatic prostate cancer. concept and implications.].
Carrasco Valiente J; Ruiz García JM; Requena Tapia MJ
Arch Esp Urol; 2018 Mar; 71(3):239-246. PubMed ID: 29633944
[TBL] [Abstract][Full Text] [Related]
19. [Definitions of oligometastatic disease and new treatment concepts].
Kissel M; Helou J; Thariat J
Bull Cancer; 2018; 105(7-8):696-706. PubMed ID: 29935914
[TBL] [Abstract][Full Text] [Related]
20. Oligometastatic Prostate Cancer.
Navrátil J; Poprach A; Lakomý R; Kocák I; Vašina J; Krupa P; Vyzula R
Klin Onkol; 2019; 32(2):97-100. PubMed ID: 30995848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
